The announcement has triggered a wave of concerns among users of eye-care products, particularly in those designed to alleviate dry and irritated eyes.
This week, the FDA raised alarms about bacterial contamination in over two dozen eye-care products, urging consumers to steer clear of these items.
The contamination was discovered at manufacturing facilities; however, no injuries have been reported as of now.
The announcement has triggered a wave of concerns among users of eye-care products, particularly in those designed to alleviate dry and irritated eyes.
Earlier this year, federal regulators initiated two voluntary recalls of unsterile, preservative-free eyedrops due to a bacterial infection outbreak. This outbreak resulted in at least 14 cases of permanent vision loss and four deaths. Hundreds of potentially unsafe eye drops were also reported to the FDA in June.
Today, the FDA has emphasized the heightened scrutiny it’s applying to eye-care products due to their direct application into the eye, bypassing some of the body's natural defenses.
As these concerns rise, The Washington Post spoke with experts to provide insight on the eye drop warnings and recalls.
FDA spokesman Jeremy Kahn told The Post that surveillance has increased in recent months after a decline during the pandemic, potentially contributing to more regulatory actions.
Though, most of the concern centers on the question, "Are these eye drops still safe?" as millions of Americans use eyedrops for conditions such as dry eye, glaucoma and itchiness caused by allergies or air pollution.
Amidst the uncertainties, Christopher Starr, a spokesperson for the American Academy of Ophthalmology, reassured in the article that eye drops are generally safe. He encouraged users to feel confident if their products haven't been mentioned in a recall.
However, T. Mark Johnson, a retina specialist, advised consumers through The Post to stick to products from major manufacturers, emphasizing their well-established protocols and safety testing.
Johnson highlighted that recent issues are often centered around smaller producers of off-brand or "no-name" drops.
Mina Massaro-Giordano, a clinical ophthalmology professor, also spoke to The Post and urged caution, and recommended consulting with eye doctors for trusted product recommendations.
Massaro-Giordano noted the importance of opting for established companies with a long-standing reputation.
The article also addressed the question of using expired eye drops.
Johnson also stressed the importance of checking expiration dates, discarding expired products and using proper application techniques to minimize the risk of contamination.
The FDA's recent warnings have urged a reevaluation of eye-care product safety, with experts providing guidance on choosing safe brands and ensuring proper use to maintain best eye care practices.
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Positive Long-term Results Seen with Vabysmo in Retinal Vein Occlusion
October 10th 2023The FDA is currently reviewing a supplemental biologics license application for Vabysmo in patients with macular edema due to retinal vein occlusion. A decision from the FDA is expected in late 2023.
Read More
The authors of a case series reported in today's edition of JAMA Ophthalmology say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters. Of the 55 patients treated with Syfovre, 16 developed floaters.
Read More